SDGR logo

SCHRODINGER INC

SDGRNASDAQ
🏆 #1885 by market capEarnings Nov 4US Equity
$30.84▲ $4.11 (+15.38%)
After hours · at close
🔔
Track SDGR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 15.4%
7d▲ 29.1%
14d▲ 23.1%
30d▲ 4.6%
ytd▲ 72.6%
1y▲ 41.8%
🏦Market Cap
$2.31B
Small Cap
📈Revenue Growth (YoY)
23.3%
Healthy
📊Gross Margin
56.9%
Healthy
💵FCF Margin
-12.5%
Thin
⚖️P/S Ratio
7.7x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$27.19 – $31.03
52-Week Range
$10.95 – $33.78
Volume (shares)
225,343
Avg Volume (shares)
—
Shares Outstanding
74.8M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$256M
Last Q Revenue
$59M
P/E Ratio
-36.1
P/S Ratio
7.7x
EPS (TTM)
$-0.73
Dividend Yield
0.00%
Dilution (1yr)
+1.1%
SDGR logo

SCHRODINGER INC

SDGR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$256M▲ +23.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
55.7%▼ −12.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$167M▼ −20.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$12M▼ −107.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
73.4M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$121M▲ +$92M YoY
StockOtter · stockotter.space

About SCHRODINGER INC

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100

Analyst Ratings

ⓘ
Consensus
Buy
13 analysts
Strong Buy3
Buy7
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.